Telomir Pharmaceuticals, Inc./$TELO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
Ticker
$TELO
Sector
Primary listing
Employees
-
Headquarters
Website
TELO Metrics
BasicAdvanced
$43m
-
-$0.29
-
-
Price and volume
Market cap
$43m
52-week high
$3.10
52-week low
$1.05
Average daily volume
93k
Financial strength
Current ratio
6.998
Quick ratio
6.721
Total debt to equity
4.088
Interest coverage (TTM)
-7,768.74%
Profitability
Management effectiveness
Return on assets (TTM)
-186.93%
Return on equity (TTM)
-384.26%
Valuation
Price to book
8.66
Price to tangible book (TTM)
8.66
Price to free cash flow (TTM)
-8.918
Free cash flow yield (TTM)
-11.21%
Free cash flow per share (TTM)
-0.14
Growth
Earnings per share change (TTM)
-31.20%
3-year earnings per share growth (CAGR)
82.12%
TELO News
AllArticlesVideos
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
Accesswire·3 days ago
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
Accesswire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs